23andMe and GSK start clinical trials for cancer drug
A collaboration between 23andMe and GSK is using genetic profiling for drug discovery
A collaboration between 23andMe and GSK is using genetic profiling for drug discovery
iCAD has launched ProFound AI Risk to provide accurate two-year, breast cancer risk evaluation, based only on a screening mammogram
The social network for cancer will use the funds to expand its service and enter new markets through its patient engagement platform
There isn’t any aspect of healthcare that isn’t being transformed by technology. The health-related technologies on display reflected the work that is being done to prevent illness, to deliver more effective treatments, and to reduce the growing cost of healthcare.
The UK’s Department of Health and Social Care has today announced the launch of a pilot programme for the new NHSX, working with clinicians and policymakers in cancer and mental health. If successful, the approach will be rolled out across the NHS.
The Gustave Roussy Institut, a cancer centre in France, is to deploy blockchain in data-sharing applications for oncology research. The technology will be built in partnership with Embleema, a developer of a healthcare blockchain network, and will be used to improve transparency, patient safety and patient engagement in clinical trials.
NHS England wants to catch lung cancer before it’s too late with the roll-out of mobile scanning units. £70 million is going to fund ten projects to check people at highest risk.
Genomics England has selected QIAGEN to provide bioinformatic support to the NHS Genomic Medicine Service and its national network of Genomic Laboratory Hubs for 5 million genome project.
For radiation oncologists, the laborious task of determining the treatment plan for cancer patients is being simplified and shortened with the application of AI software from Finnish company MVision.
A collaboration between Aether, the Californian bioprinter startup, and University College London (UCL) promises to develop a powerful new approach to 3D printing nanotechnology, while greatly reducing the cost compared with competitor offerings.